Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 12/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL29195223 | 0.97 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL1109741 | 0.95 | OPRL1 (0.57) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL4556223 | 0.92 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL16469256 | 0.92 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL1041473 | 0.92 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL60129 | 0.92 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL29195226 | 0.92 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1POLB | |
| Hydrogen Peroxide SCHEMBL14842577 | 0.92 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL1040024 | 0.92 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL9022765 | 0.90 | OPRL1 (0.48) | OPRL1OPRM1OPRK1OPRD1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117718081-A | Tetravalent uranium photocatalyst and synthesis method thereof | 南京大学 | 2024-03-19 | — | — | CN | claimed |
| CN-122071411-A | Method for forming ester by oxidizing and breaking carbon-carbon bond by tertiary alcohol | 中国科学院大连化学物理研究所 | 2026-05-22 | — | — | CN | disclosed |
| CN-118930426-A | Method for preparing benzoic acid and derivatives thereof from tertiary alcohol | 中国科学院大连化学物理研究所 | 2024-11-12 | — | — | CN | disclosed |
| CN-117718081-A | Tetravalent uranium photocatalyst and synthesis method thereof | 南京大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-117603090-A | Method for breaking and forming tetravalent uranium photocatalytic carbon-carbon bond | 南京大学 | 2024-02-27 | — | — | CN | disclosed |
| CN-115894141-B | Method for synthesizing acyl indene alkane derivative | 贺州学院 | 2023-12-22 | — | — | CN | disclosed |
| CN-115894141-A | Synthesis method of acylindene derivatives | 贺州学院 | 2023-04-04 | — | — | CN | disclosed |
| CN-113651752-B | Synthesis method of 2-aroylquinoline derivative | 温州大学 | 2023-02-10 | — | — | CN | disclosed |
| CN-113636977-B | Synthesis method of 2-aryl benzazepine and derivatives thereof | 温州大学 | 2022-12-20 | — | — | CN | disclosed |
| CN-112110801-B | Synthetic method of gamma-aryl substituted ketone compound | 浙江工业大学 | 2022-07-19 | — | — | CN | disclosed |
| US-20070219265-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2007-09-20 | — | — | US | disclosed |
| US-20070219265-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2007-09-20 | — | — | US | disclosed |
| CN-1344270-A | Functionalized heterocycles as chemokine receptor modulators | THOUSAND YEARS MEDICAMENTS INC (US) | 2002-04-10 | — | — | CN | disclosed |
| EP-1144415-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-0682663-B1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | UPJOHN CO (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000042045-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| US-5686486-A | 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl b!pyran-2-ones useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0682663-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-22 | — | — | EP | disclosed |
| WO-1994018188-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | THE UPJOHN COMPANY (US) | 1994-08-18 | — | — | WO | disclosed |
| US-4256618-A | DISCOLORATION INHIBITION DURING EARLY HEATING; SYNERGISTIC | ARGUS CHEMICAL CORPORATION (US) | 1981-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219265-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | OPRL1 2323/4885OPRM1 1425/4885OPRK1 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.